Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 70Neoplasm Metastasis 20Rectal Neoplasms 19Colonic Neoplasms 17Neoplasms 11Cholangiocarcinoma 7Carcinoma, Non-Small-Cell Lung 7Head and Neck Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Carcinoma, Squamous Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4Ovarian Neoplasms 4Lung Neoplasms 4Colorectal Cancer Metastatic 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Prostatic Neoplasms 3Inflammatory Breast Neoplasms 3Carcinoma 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Fallopian Tube Neoplasms 2Biliary Tract Neoplasms 2Uterine Cervical Neoplasms 1Serotonin Syndrome 1Salivary Gland Malignancy 1

Interventions

Panitumumab 1Gemcitabine 1Cystectomy 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Cone Dystrophy 3 × Panitumumab × Clear all
NCT01916109 2016-02-12

Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Terminated
4 enrolled 6 charts
Genitourinary

Cone Dystrophy 3, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡